烟酰胺体外扩增单一脐血单位作为独立移植物进行干细胞移植的I/II期研究
36例血液系统恶性肿瘤患者在11个中心接受烟酰胺体外扩增脐血单位作为独立移植物移植。42天中性粒细胞植入累积发生率为94%。与标准化脐血移植相比,中性粒细胞恢复中位时间缩短9.5天,血小板恢复中位时间缩短12天。该试验证实了体外扩增脐血单位作为独立移植物的可行性、安全性和有效性。
要点
- 烟酰胺体外扩增脐血单位作为独立移植物移植,42天中性粒细胞植入累积发生率为94%。
- 中性粒细胞恢复中位时间11.5天(扩增组)vs 21天(对照组),缩短9.5天。
- 血小板恢复中位时间34天(扩增组)vs 46天(对照组),缩短12天。
核心结论
- 烟酰胺体外扩增脐血单位可缩短中性粒细胞恢复中位时间9.5天(95% CI,7至12天)和血小板恢复中位时间12天(95% CI,3至16.5天)。
- 该试验证实了体外扩增脐血单位作为独立移植物的可行性、安全性和有效性。
研究设计与样本
- I/II期研究,36例血液系统恶性肿瘤患者在11个中心接受清髓性预处理后移植烟酰胺体外扩增的单一脐血单位作为独立造血干细胞移植物。
主要发现
- 42天中性粒细胞植入累积发生率为94%。
- 2例患者因病毒感染发生继发性植入失败。
- 中性粒细胞恢复中位时间:烟酰胺扩增脐血组11.5天(95% CI,9至14天)vs 国际血液和骨髓移植研究中心报告的标准化脐血移植对照组(n=146)21天(95% CI,20至23天),P < .001。
- 血小板恢复中位时间:扩增组34天(95% CI,32至42天)vs 对照组46天(95% CI,42至50天),P < .001。
- 100天2至4级急性移植物抗宿主病(GVHD)累积发生率为44%,100天3和4级急性GVHD为11%;2年所有慢性GVHD累积发生率为40%,中/重度慢性GVHD为10%;2年非复发死亡率和复发累积发生率分别为24%和33%;2年总生存率和无病生存率分别为51%和43%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed the safety and efficacy of a UCB graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft. METHODS: Thirty-six patients with hematologic malignancies underwent transplantation at 11 sites. RESULTS: The cumulative incidence of neutrophil engraftment at day 42 was 94%. Two patients experienced secondary graft failure attributable to viral infections. Hematopoietic recovery was compared with that observed in recipients of standard UCB transplantation as reported to the Center for International Blood and Marrow Transplant Research (n = 146). The median time to neutrophil recovery was 11.5 days (95% CI, 9 to 14 days) for recipients of nicotinamide-expanded UCB and 21 days (95% CI, 20 to 23 days) for the comparator ( P < .001). The median time to platelet recovery was 34 days (95% CI, 32 to 42 days) and 46 days (95% CI, 42 to 50 days) for the expanded and the comparator cohorts, respectively ( P < .001). The cumulative incidence of grade 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 44%, and grade 3 and 4 acute GVHD at day 100 was 11%. The cumulative incidence at 2 years of all chronic GVHD was 40%, and moderate/severe chronic GVHD was 10%. The 2-year cumulative incidences of nonrelapse mortality and relapse were 24% and 33%, respectively. The 2-year probabilities of overall and disease-free survival were 51% and 43%, respectively. CONCLUSION: UCB expanded ex vivo with nicotinamide shortens median neutrophil recovery by 9.5 days (95% CI, 7 to 12 days) and median platelet recovery by 12 days (95% CI, 3 to 16.5 days). This trial establishes feasibility, safety, and efficacy of an ex vivo expanded UCB unit as a stand-alone graft.
引用
- Horwitz ME, Wease S, Blackwell B, et al. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J Clin Oncol. 2018. PMID: 30523748. doi:10.1200/JCO.18.00053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。